News Roche poised to buy MASH drug developer 89bio for $3.5bn Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.
News 89bio shows its NASH hand, boosting FGF21 concept Positive phase 2b results on liver fibrosis follow similar data with a rival drug from Akero.
News BioNTech sticks with cancer vaccine despite trial miss BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.